About
Terapet SA is a MedTech company based in Geneva, established in December 2019 as a spin-off from CERN. Founded by experts in applied physics, engineering, and radiation oncology, the company focuses on developing and manufacturing gamma-ray detection systems and integrated imaging solutions for nuclear medicine. Its mission is to enhance the quality and clarity of diagnostic imaging and treatment in this field. Terapet's flagship products include Qualyscan™, an all-in-one solution for patient-specific quality assurance in proton and carbon ion therapy, which is currently being commercialized. Another key product is Nuclyscan™ (also known as Claryscan™), a total-body PET scanner designed for theranostic applications, which is in research and development with a planned delivery around 2026. Terapet serves hospitals, pharmaceutical companies, research centers, and proton therapy facilities, aiming to advance cancer diagnosis and treatment. The company has received notable funding and recognition, supporting its efforts in clinical validation and innovation in precision medicine.
Technologies
Keywords
Company Information
- Employees12
- Founded2019
- Total Funding$2590645
Location
7 Rue du Pre-Bouvier, Meyrin, Geneva, Switzerland, 1217
